Filing Flows

Filing Flows › Health Care › Opus Genetics (IRD)

Opus Genetics (IRD) earnings and revenue breakdown

Latest: Q2 2026 · 10-Q filed Aug 6, 2026 · Opus Genetics (IRD) Q2 2026 earnings results →

Q2 2026 Revenue down 74% year over year to $755K

Opus Genetics made $755K in Q2 2026 (-74% Y/Y). Operating margin n/m, net loss $8.1M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 6, 2026.

Revenue$755K
Year over year-74%
Operating marginn/m
Net earnings−$8.1M
Operating cash flow−$11.9M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $755K in Q2 2026, down 74% year over year and down 65% from the previous quarter.

Operating costs exceeded revenue by $16.5M, an operating margin of -2182.8%. Total costs grew 46% against a revenue fall of 74%. The fastest-growing cost line was Research & development (+86%). The quarter ended with a net loss of $8.1M, narrower than the previous quarter's $65.5M loss. Non-operating items added $8.4M, -104% of pre-tax earnings, so the bottom line overstates operating performance.

Operating cash flow was −$11.9M. Non-cash charges added back $14K of depreciation and $1.4M of share-based compensation. Working capital and other items used $5.3M.

Quarterly history

Opus Genetics revenue by quarterOpus Genetics revenue by quarter$4.3MQ4 2024$4.4MQ1 2025$2.9MQ2 2025$3.1MQ3 2025$3.9MQ4 2025$2.2MQ1 2026$755KQ2 2026
Opus Genetics net earnings by quarterOpus Genetics net earnings by quarter−$35.1MQ4 2024−$8.2MQ1 2025−$7.4MQ2 2025−$17.5MQ3 2025−$16.5MQ4 2025−$65.5MQ1 2026−$8.1MQ2 2026
QuarterFormFiledRevenueY/YOp. marginNet earningsOp. cash flow
Q2 202610-QAug 6, 2026$755K-74%n/m−$8.1M−$11.9M
Q1 202610-QMay 12, 2026$2.2M-51%-665.9%−$65.5M−$12.7M
Q4 202510-KMar 12, 2026$3.9M-10%-296.3%−$16.5M−$9.8M
Q3 202510-QNov 12, 2025$3.1M-20%-269.9%−$17.5M−$6.2M
Q2 202510-QAug 13, 2025$2.9M+159%-309.0%−$7.4M−$10.3M
Q1 202510-QMay 15, 2025$4.4M+155%-227.2%−$8.2M−$9.0M
Q4 202410-KMar 31, 2025$4.3M+154%-884.0%−$35.1M−$7.4M

Charts

Opus Genetics: revenue growth, year over year and quarter over quarterOpus Genetics: revenue growth, year over year and quarter over quarterY/YQ/Q+154%Q4 2024+155%+2%Q1 2025+159%-34%Q2 2025-20%+7%Q3 2025-10%+26%Q4 2025-51%-44%Q1 2026-74%-65%Q2 2026
Latest (Q2 2026): Y/Y -74%, Q/Q -65%.
Opus Genetics: where the cash came from (+) and went (−), TTM to Q2 2026Opus Genetics: where the cash came from (+) and went (−), TTM to Q2 2026Other financing$87.9MCash drawn (+) / kept (−)−$56.5MOperating cash flow−$40.7MShares issued$9.2M
From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.
Opus Genetics: profit against cash, quarter by quarterOpus Genetics: profit against cash, quarter by quarterNet incomeOperating cash flow−$7.5M−$5.1MQ3 2024−$35.1M−$7.4MQ4 2024−$8.2M−$9.0MQ1 2025−$7.4M−$10.3MQ2 2025−$17.5M−$6.2MQ3 2025−$16.5M−$9.8MQ4 2025−$65.5M−$12.7MQ1 2026−$8.1M−$11.9MQ2 2026
Latest (Q2 2026): Net income −$8.1M, Operating cash flow −$11.9M.
Opus Genetics: diluted shares by fiscal year (split-adjusted)Opus Genetics: diluted shares by fiscal year (split-adjusted)14MFY202015MFY202121MFY202222MFY202327MFY202462MFY2025
+345.0% since FY2020: more shares outstanding (issuance, stock pay); earlier years scaled for the 3-for-1 split before FY2021.
Opus Genetics in its industry: growth against margin (225 companies, SIC 2834)Opus Genetics in its industry: growth against margin (225 companies, SIC 2834)revenue growth, year over year →↑ operating marginmedian +11%median -50%JNJLLYMRKABBVPFEBMYABTREGNTEVAVTRSVRTXBHCZTSONCOGNALNYELANJAZZBMRNPRGOAMRXUTHRRPRXNRIXINSMKeenova Therapeutics plcALKSMDGLPAHCSRPTPTCTINDVBBIOACADCORTPBHANIPKNSAPTGXHRMYIONSAXSMTGTXSUPNTVTXCOLLVREOFAMPHMIRMPCRXRARELQDAARQTIRWDARDXNATRXNCREBSZLABXERSINVACRMDMNKDRYTMURGNPHATAUPHSNDXRIGLLGNDEOLSARWRPGENHROWVNDAOPKSDGRGERNETONAGIOPBYITNGXCYRXCYTKMRVIORGONUVBLFVNSIGAKROSAMRNZVRASPRYHRTXAKBABCYCKPTIGYREMGNXELTPSEPNVRDNLFCRCrinetics Pharmaceuticals, Inc.VSTMKURATBPHLABADCTNAMSFBIOXLODERMARCTRMTIAYTUFHTXENTATNXPOCULASMBWVEAPMDBFRIABEOSTOKLXRXCAPRIDYANKTRZOMDFINBPJANXSBFMGOSSETSTRCUSCPIXLIFDCUEAQSTPRAXWHWKVERUEMMAGENBVRCACELUQUREZYMEEQABCLIMNMKYNBAKTSRNACVSICNTBTRAWISCOEVFMTVRDLPCNCAMPAtaiBeckley Inc.CTMXALMSPMHSACRSVTGNROIVKRROJAGXENSCKRSAABUSPRPHSTTKCPHITRDATXMDGOVXNWBOBIOEUPBOVIDSPRBXBIOPRTAMCRBARVNMNOVSLNIGCBIOALGVNDNTHCPMDSPRORFLCOYASCYXBFRGSXTPBTAIQHCWBSERYARWRNACRGBPAVTXCLNNNTHIHINDAAGHALTONCOCRVOSKVIBOLTBDPTLYELIBOPULMIRD (-74%, -100%)
Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.

Interactive views

The same charts as the app — open one to draw it.

💵Where each $1 goesinteractive

Loading the interactive chart…

🌏Named in Asian annual reportsinteractive

Loading the interactive chart…

🔄Rotation against the market and its industry (RRG)interactive

Loading the interactive chart…

🔍Earnings qualityinteractive

Loading the interactive chart…

⚖️Fair value by methodinteractive

Loading the interactive chart…

🔭Outlook & guidanceinteractive

Loading the interactive chart…

📈Investments: gains and what it boughtinteractive

Loading the interactive chart…

🏭Its industry’s money flow (input-output)interactive

Loading the interactive chart…

About Opus Genetics

Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

In its own words, from its 8-K, filed Aug 6, 2026.

Opus Genetics against its Pharmaceutical Preparations peers

The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -74% against the peers' median +7%.

CompanyQuarterRevenueY/YOp. margin
IRD Opus GeneticsQ2 2026$755K-74%n/m
JNJ Johnson & JohnsonQ3 2026$25.4B+6%0.1%
LLY ELI LillyQ3 2026$24.4B+39%34.5%
MRK MerckQ3 2026$18.1B+5%30.7%
ABBV AbbVieQ3 2026$17.4B+10%36.0%
PFE PfizerQ3 2026$16.6B-0.4%20.4%
BMY Bristol Myers SquibbQ3 2026$13.1B+7%19.4%
ABT Abbott LaboratoriesQ3 2026$13.0B+14%10.4%
REGN Regeneron PharmaceuticalsQ3 2026$5.1B+36%40.0%

Source: Opus Genetics 10-Q on SEC EDGAR · CIK 1228627 · Pharmaceutical Preparations

13F: who owns IRD and who is buying

Largest holders of IRD (13F)Largest holders of IRD (13F)Nantahala Capital Management, LLC$25.2MCaligan Partners LP$25.0MAdage Capital Partners GP, L.L.C.$24.8MBios Capital Management, LP$15.1MBlackRock$12.8MBalyasny Asset Management L.P.$12.7MVanguard Capital Management LLC$12.2MBoxer Capital Management, LLC$11.6MTrails Edge Capital Partners, LP$11.3MMillennium Management LLC$9.5M
Funds' net buying of IRD by quarter (13F)Funds' net buying of IRD by quarter (13F)−$306K2024-09−$27K2024-12$10.2M2025-03$3.4M2025-06$2.1M2025-09$17.7M2025-12$73.2M2026-03−$3.2M2026-06
Value of shares 13F filers added minus the value they sold, each quarter (quarters with most filings in).

More on IRD

History

Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results

Compare IRD with

中文版：Opus Genetics（IRD）财报

Español · Français